Trimetaphan camsilate
| Clinical data | |
|---|---|
| Trade names | Arfonad |
| Routes of administration | Oral, IM, IV |
| ATC code | |
| Pharmacokinetic data | |
| Excretion | Renal, mostly unchanged |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.633 |
| Chemical and physical data | |
| Formula | C22H25N2OS (free base) |
| Molar mass | 365.52 g·mol−1 |
| (what is this?) (verify) | |
Trimetaphan camsilate (INN) or trimethaphan camsylate (USAN), sold under the trade name Arfonad, is a sympatholytic drug that is infrequently used to lower blood pressure.
Trimetaphan is a ganglionic blocker: it counteracts cholinergic transmission at the a specific type of nicotinic acetylcholine receptors in the autonomic ganglia and, therefore, blocks both the sympathetic nervous system and the parasympathetic nervous system. It functions as a non-depolarizing competitive antagonist at the nicotinic receptor, has a short duration of action, and is administered intravenously.
It was discovered by Leo Sternbach.